Trial Profile
A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Cancer in Late Relapse (>6 months)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Sep 2023
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms CALYPSO
- 24 May 2017 Results comparing Trabectedin-Based Versus Platinum-Based Treatment in Relapsed, Partially Platinum Sensitive Ovarian Cancer patients from two randomised trials (OVA-301 and CALYPSO) presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 13 Jan 2014 Status changed from active, no longer recruiting to completed as reported in ClinicalTrials.gov record.
- 03 Nov 2012 Planned number of patients changed from 864 to 974.